nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00529	0.0596	CbGpPWpGaD
Arformoterol—Cystitis noninfective—Doxorubicin—bone cancer	0.00328	0.0036	CcSEcCtD
Arformoterol—Melaena—Doxorubicin—bone cancer	0.00328	0.0036	CcSEcCtD
Arformoterol—Cystitis—Doxorubicin—bone cancer	0.00324	0.00356	CcSEcCtD
Arformoterol—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00322	0.0363	CbGpPWpGaD
Arformoterol—Candida infection—Doxorubicin—bone cancer	0.00321	0.00352	CcSEcCtD
Arformoterol—Immune system disorder—Cisplatin—bone cancer	0.00321	0.00352	CcSEcCtD
Arformoterol—Mediastinal disorder—Cisplatin—bone cancer	0.0032	0.00351	CcSEcCtD
Arformoterol—Arrhythmia—Cisplatin—bone cancer	0.00317	0.00348	CcSEcCtD
Arformoterol—Abnormal vision—Epirubicin—bone cancer	0.00317	0.00348	CcSEcCtD
Arformoterol—Malnutrition—Cisplatin—bone cancer	0.00309	0.00339	CcSEcCtD
Arformoterol—Cramps of lower extremities—Doxorubicin—bone cancer	0.00309	0.00339	CcSEcCtD
Arformoterol—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00305	0.0344	CbGpPWpGaD
Arformoterol—Bladder pain—Doxorubicin—bone cancer	0.00304	0.00333	CcSEcCtD
Arformoterol—Neoplasm—Doxorubicin—bone cancer	0.00304	0.00333	CcSEcCtD
Arformoterol—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00298	0.0336	CbGpPWpGaD
Arformoterol—Muscle spasms—Cisplatin—bone cancer	0.00297	0.00326	CcSEcCtD
Arformoterol—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00296	0.0334	CbGpPWpGaD
Arformoterol—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00294	0.0331	CbGpPWpGaD
Arformoterol—Abnormal vision—Doxorubicin—bone cancer	0.00293	0.00322	CcSEcCtD
Arformoterol—Cardiac failure congestive—Epirubicin—bone cancer	0.00291	0.00319	CcSEcCtD
Arformoterol—Tremor—Cisplatin—bone cancer	0.0029	0.00318	CcSEcCtD
Arformoterol—Ill-defined disorder—Cisplatin—bone cancer	0.00287	0.00315	CcSEcCtD
Arformoterol—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00281	0.0317	CbGpPWpGaD
Arformoterol—Malaise—Cisplatin—bone cancer	0.00279	0.00306	CcSEcCtD
Arformoterol—Hypoglycaemia—Epirubicin—bone cancer	0.0027	0.00296	CcSEcCtD
Arformoterol—Cardiac failure congestive—Doxorubicin—bone cancer	0.00269	0.00295	CcSEcCtD
Arformoterol—Myalgia—Cisplatin—bone cancer	0.00263	0.00289	CcSEcCtD
Arformoterol—Anxiety—Cisplatin—bone cancer	0.00262	0.00288	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00261	0.00287	CcSEcCtD
Arformoterol—Discomfort—Cisplatin—bone cancer	0.0026	0.00285	CcSEcCtD
Arformoterol—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.00255	0.0288	CbGpPWpGaD
Arformoterol—Oedema—Cisplatin—bone cancer	0.00252	0.00277	CcSEcCtD
Arformoterol—Anaphylactic shock—Cisplatin—bone cancer	0.00252	0.00277	CcSEcCtD
Arformoterol—Infection—Cisplatin—bone cancer	0.00251	0.00275	CcSEcCtD
Arformoterol—Hypoglycaemia—Doxorubicin—bone cancer	0.0025	0.00274	CcSEcCtD
Arformoterol—Nervous system disorder—Cisplatin—bone cancer	0.00247	0.00271	CcSEcCtD
Arformoterol—Tachycardia—Cisplatin—bone cancer	0.00246	0.0027	CcSEcCtD
Arformoterol—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00245	0.0277	CbGpPWpGaD
Arformoterol—Dehydration—Epirubicin—bone cancer	0.00245	0.00269	CcSEcCtD
Arformoterol—Skin disorder—Cisplatin—bone cancer	0.00245	0.00269	CcSEcCtD
Arformoterol—Asthma—Methotrexate—bone cancer	0.00243	0.00267	CcSEcCtD
Arformoterol—Dry skin—Epirubicin—bone cancer	0.00242	0.00265	CcSEcCtD
Arformoterol—Hypokalaemia—Epirubicin—bone cancer	0.0024	0.00263	CcSEcCtD
Arformoterol—Hypotension—Cisplatin—bone cancer	0.00236	0.00259	CcSEcCtD
Arformoterol—Nasopharyngitis—Epirubicin—bone cancer	0.00236	0.00259	CcSEcCtD
Arformoterol—Gastritis—Epirubicin—bone cancer	0.00233	0.00256	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Cisplatin—bone cancer	0.0023	0.00252	CcSEcCtD
Arformoterol—Asthma—Epirubicin—bone cancer	0.00228	0.0025	CcSEcCtD
Arformoterol—Influenza—Epirubicin—bone cancer	0.00228	0.0025	CcSEcCtD
Arformoterol—Dehydration—Doxorubicin—bone cancer	0.00227	0.00249	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Methotrexate—bone cancer	0.00226	0.00248	CcSEcCtD
Arformoterol—Dyspnoea—Cisplatin—bone cancer	0.00225	0.00247	CcSEcCtD
Arformoterol—Dry skin—Doxorubicin—bone cancer	0.00224	0.00245	CcSEcCtD
Arformoterol—Hypokalaemia—Doxorubicin—bone cancer	0.00222	0.00244	CcSEcCtD
Arformoterol—Angina pectoris—Epirubicin—bone cancer	0.00222	0.00244	CcSEcCtD
Arformoterol—Bronchitis—Epirubicin—bone cancer	0.00219	0.0024	CcSEcCtD
Arformoterol—Nasopharyngitis—Doxorubicin—bone cancer	0.00218	0.00239	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Cisplatin—bone cancer	0.00218	0.00239	CcSEcCtD
Arformoterol—Gastritis—Doxorubicin—bone cancer	0.00216	0.00237	CcSEcCtD
Arformoterol—Pain—Cisplatin—bone cancer	0.00216	0.00237	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Epirubicin—bone cancer	0.00212	0.00232	CcSEcCtD
Arformoterol—Conjunctivitis—Methotrexate—bone cancer	0.00211	0.00232	CcSEcCtD
Arformoterol—Influenza—Doxorubicin—bone cancer	0.00211	0.00231	CcSEcCtD
Arformoterol—Asthma—Doxorubicin—bone cancer	0.00211	0.00231	CcSEcCtD
Arformoterol—Feeling abnormal—Cisplatin—bone cancer	0.00208	0.00228	CcSEcCtD
Arformoterol—Haematuria—Methotrexate—bone cancer	0.00207	0.00227	CcSEcCtD
Arformoterol—Hyperglycaemia—Epirubicin—bone cancer	0.00206	0.00226	CcSEcCtD
Arformoterol—Angina pectoris—Doxorubicin—bone cancer	0.00205	0.00225	CcSEcCtD
Arformoterol—Bronchitis—Doxorubicin—bone cancer	0.00203	0.00222	CcSEcCtD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.00202	0.0227	CbGpPWpGaD
Arformoterol—ADRB2—Arf6 signaling events—GNA11—bone cancer	0.00201	0.0227	CbGpPWpGaD
Arformoterol—Body temperature increased—Cisplatin—bone cancer	0.00199	0.00219	CcSEcCtD
Arformoterol—Urinary tract infection—Epirubicin—bone cancer	0.00197	0.00217	CcSEcCtD
Arformoterol—Conjunctivitis—Epirubicin—bone cancer	0.00197	0.00217	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00196	0.00215	CcSEcCtD
Arformoterol—Haematuria—Epirubicin—bone cancer	0.00194	0.00213	CcSEcCtD
Arformoterol—Pharyngitis—Methotrexate—bone cancer	0.00193	0.00212	CcSEcCtD
Arformoterol—Urinary tract disorder—Methotrexate—bone cancer	0.00192	0.00211	CcSEcCtD
Arformoterol—Urethral disorder—Methotrexate—bone cancer	0.00191	0.0021	CcSEcCtD
Arformoterol—Sinusitis—Epirubicin—bone cancer	0.00191	0.00209	CcSEcCtD
Arformoterol—Hyperglycaemia—Doxorubicin—bone cancer	0.0019	0.00209	CcSEcCtD
Arformoterol—Visual impairment—Methotrexate—bone cancer	0.00188	0.00206	CcSEcCtD
Arformoterol—Hypersensitivity—Cisplatin—bone cancer	0.00186	0.00204	CcSEcCtD
Arformoterol—Rhinitis—Epirubicin—bone cancer	0.00183	0.00201	CcSEcCtD
Arformoterol—Conjunctivitis—Doxorubicin—bone cancer	0.00183	0.002	CcSEcCtD
Arformoterol—Urinary tract infection—Doxorubicin—bone cancer	0.00183	0.002	CcSEcCtD
Arformoterol—Asthenia—Cisplatin—bone cancer	0.00181	0.00199	CcSEcCtD
Arformoterol—Pharyngitis—Epirubicin—bone cancer	0.00181	0.00199	CcSEcCtD
Arformoterol—Cardiac disorder—Methotrexate—bone cancer	0.00181	0.00198	CcSEcCtD
Arformoterol—Urinary tract disorder—Epirubicin—bone cancer	0.0018	0.00198	CcSEcCtD
Arformoterol—Oedema peripheral—Epirubicin—bone cancer	0.0018	0.00197	CcSEcCtD
Arformoterol—Haematuria—Doxorubicin—bone cancer	0.00179	0.00197	CcSEcCtD
Arformoterol—Connective tissue disorder—Epirubicin—bone cancer	0.00179	0.00197	CcSEcCtD
Arformoterol—Urethral disorder—Epirubicin—bone cancer	0.00179	0.00196	CcSEcCtD
Arformoterol—Sinusitis—Doxorubicin—bone cancer	0.00176	0.00193	CcSEcCtD
Arformoterol—Immune system disorder—Methotrexate—bone cancer	0.00176	0.00193	CcSEcCtD
Arformoterol—Visual impairment—Epirubicin—bone cancer	0.00176	0.00193	CcSEcCtD
Arformoterol—Mediastinal disorder—Methotrexate—bone cancer	0.00176	0.00193	CcSEcCtD
Arformoterol—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00175	0.0198	CbGpPWpGaD
Arformoterol—Diarrhoea—Cisplatin—bone cancer	0.00173	0.00189	CcSEcCtD
Arformoterol—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00171	0.0193	CbGpPWpGaD
Arformoterol—Mental disorder—Methotrexate—bone cancer	0.00171	0.00187	CcSEcCtD
Arformoterol—Malnutrition—Methotrexate—bone cancer	0.0017	0.00186	CcSEcCtD
Arformoterol—Cardiac disorder—Epirubicin—bone cancer	0.00169	0.00186	CcSEcCtD
Arformoterol—Rhinitis—Doxorubicin—bone cancer	0.00169	0.00186	CcSEcCtD
Arformoterol—Pharyngitis—Doxorubicin—bone cancer	0.00167	0.00184	CcSEcCtD
Arformoterol—Urinary tract disorder—Doxorubicin—bone cancer	0.00167	0.00183	CcSEcCtD
Arformoterol—Oedema peripheral—Doxorubicin—bone cancer	0.00166	0.00182	CcSEcCtD
Arformoterol—Dysgeusia—Methotrexate—bone cancer	0.00166	0.00182	CcSEcCtD
Arformoterol—Connective tissue disorder—Doxorubicin—bone cancer	0.00166	0.00182	CcSEcCtD
Arformoterol—Urethral disorder—Doxorubicin—bone cancer	0.00165	0.00181	CcSEcCtD
Arformoterol—Immune system disorder—Epirubicin—bone cancer	0.00165	0.00181	CcSEcCtD
Arformoterol—Mediastinal disorder—Epirubicin—bone cancer	0.00164	0.0018	CcSEcCtD
Arformoterol—Back pain—Methotrexate—bone cancer	0.00164	0.0018	CcSEcCtD
Arformoterol—Arrhythmia—Epirubicin—bone cancer	0.00163	0.00179	CcSEcCtD
Arformoterol—Visual impairment—Doxorubicin—bone cancer	0.00163	0.00178	CcSEcCtD
Arformoterol—Vomiting—Cisplatin—bone cancer	0.0016	0.00176	CcSEcCtD
Arformoterol—Mental disorder—Epirubicin—bone cancer	0.0016	0.00175	CcSEcCtD
Arformoterol—Rash—Cisplatin—bone cancer	0.00159	0.00175	CcSEcCtD
Arformoterol—Dermatitis—Cisplatin—bone cancer	0.00159	0.00174	CcSEcCtD
Arformoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00159	0.0179	CbGpPWpGaD
Arformoterol—Malnutrition—Epirubicin—bone cancer	0.00159	0.00174	CcSEcCtD
Arformoterol—Ill-defined disorder—Methotrexate—bone cancer	0.00157	0.00173	CcSEcCtD
Arformoterol—Cardiac disorder—Doxorubicin—bone cancer	0.00157	0.00172	CcSEcCtD
Arformoterol—Tension—Epirubicin—bone cancer	0.00156	0.00171	CcSEcCtD
Arformoterol—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00156	0.0175	CbGpPWpGaD
Arformoterol—Dysgeusia—Epirubicin—bone cancer	0.00155	0.00171	CcSEcCtD
Arformoterol—Nervousness—Epirubicin—bone cancer	0.00154	0.00169	CcSEcCtD
Arformoterol—Back pain—Epirubicin—bone cancer	0.00154	0.00168	CcSEcCtD
Arformoterol—Malaise—Methotrexate—bone cancer	0.00153	0.00168	CcSEcCtD
Arformoterol—Muscle spasms—Epirubicin—bone cancer	0.00153	0.00167	CcSEcCtD
Arformoterol—Immune system disorder—Doxorubicin—bone cancer	0.00152	0.00167	CcSEcCtD
Arformoterol—Mediastinal disorder—Doxorubicin—bone cancer	0.00152	0.00167	CcSEcCtD
Arformoterol—Arrhythmia—Doxorubicin—bone cancer	0.00151	0.00165	CcSEcCtD
Arformoterol—Nausea—Cisplatin—bone cancer	0.0015	0.00164	CcSEcCtD
Arformoterol—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.0015	0.0169	CbGpPWpGaD
Arformoterol—Cough—Methotrexate—bone cancer	0.00148	0.00162	CcSEcCtD
Arformoterol—Mental disorder—Doxorubicin—bone cancer	0.00148	0.00162	CcSEcCtD
Arformoterol—Ill-defined disorder—Epirubicin—bone cancer	0.00147	0.00162	CcSEcCtD
Arformoterol—Malnutrition—Doxorubicin—bone cancer	0.00147	0.00161	CcSEcCtD
Arformoterol—Agitation—Epirubicin—bone cancer	0.00146	0.0016	CcSEcCtD
Arformoterol—ADRB2—GPCRs, Other—GRM1—bone cancer	0.00145	0.0164	CbGpPWpGaD
Arformoterol—Arthralgia—Methotrexate—bone cancer	0.00144	0.00158	CcSEcCtD
Arformoterol—Myalgia—Methotrexate—bone cancer	0.00144	0.00158	CcSEcCtD
Arformoterol—Chest pain—Methotrexate—bone cancer	0.00144	0.00158	CcSEcCtD
Arformoterol—Tension—Doxorubicin—bone cancer	0.00144	0.00158	CcSEcCtD
Arformoterol—Dysgeusia—Doxorubicin—bone cancer	0.00144	0.00158	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00143	0.00157	CcSEcCtD
Arformoterol—Malaise—Epirubicin—bone cancer	0.00143	0.00157	CcSEcCtD
Arformoterol—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00143	0.0161	CbGpPWpGaD
Arformoterol—Discomfort—Methotrexate—bone cancer	0.00143	0.00157	CcSEcCtD
Arformoterol—Nervousness—Doxorubicin—bone cancer	0.00143	0.00157	CcSEcCtD
Arformoterol—Back pain—Doxorubicin—bone cancer	0.00142	0.00156	CcSEcCtD
Arformoterol—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00142	0.016	CbGpPWpGaD
Arformoterol—Muscle spasms—Doxorubicin—bone cancer	0.00141	0.00155	CcSEcCtD
Arformoterol—Palpitations—Epirubicin—bone cancer	0.0014	0.00154	CcSEcCtD
Arformoterol—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00139	0.0156	CbGpPWpGaD
Arformoterol—Cough—Epirubicin—bone cancer	0.00139	0.00152	CcSEcCtD
Arformoterol—Anaphylactic shock—Methotrexate—bone cancer	0.00138	0.00152	CcSEcCtD
Arformoterol—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00138	0.0155	CbGpPWpGaD
Arformoterol—Infection—Methotrexate—bone cancer	0.00138	0.00151	CcSEcCtD
Arformoterol—Hypertension—Epirubicin—bone cancer	0.00137	0.0015	CcSEcCtD
Arformoterol—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00136	0.0154	CbGpPWpGaD
Arformoterol—Ill-defined disorder—Doxorubicin—bone cancer	0.00136	0.0015	CcSEcCtD
Arformoterol—Nervous system disorder—Methotrexate—bone cancer	0.00136	0.00149	CcSEcCtD
Arformoterol—Myalgia—Epirubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Arformoterol—Arthralgia—Epirubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Arformoterol—Chest pain—Epirubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.00135	0.0152	CbGpPWpGaD
Arformoterol—Agitation—Doxorubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Arformoterol—Anxiety—Epirubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Arformoterol—Skin disorder—Methotrexate—bone cancer	0.00134	0.00148	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00134	0.00147	CcSEcCtD
Arformoterol—Discomfort—Epirubicin—bone cancer	0.00134	0.00147	CcSEcCtD
Arformoterol—Malaise—Doxorubicin—bone cancer	0.00132	0.00145	CcSEcCtD
Arformoterol—Dry mouth—Epirubicin—bone cancer	0.00132	0.00145	CcSEcCtD
Arformoterol—Palpitations—Doxorubicin—bone cancer	0.0013	0.00142	CcSEcCtD
Arformoterol—Oedema—Epirubicin—bone cancer	0.0013	0.00142	CcSEcCtD
Arformoterol—Anaphylactic shock—Epirubicin—bone cancer	0.0013	0.00142	CcSEcCtD
Arformoterol—Hypotension—Methotrexate—bone cancer	0.00129	0.00142	CcSEcCtD
Arformoterol—Infection—Epirubicin—bone cancer	0.00129	0.00141	CcSEcCtD
Arformoterol—Cough—Doxorubicin—bone cancer	0.00128	0.00141	CcSEcCtD
Arformoterol—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00128	0.0144	CbGpPWpGaD
Arformoterol—Nervous system disorder—Epirubicin—bone cancer	0.00127	0.00139	CcSEcCtD
Arformoterol—Hypertension—Doxorubicin—bone cancer	0.00127	0.00139	CcSEcCtD
Arformoterol—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00126	0.0143	CbGpPWpGaD
Arformoterol—Tachycardia—Epirubicin—bone cancer	0.00126	0.00139	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00126	0.00138	CcSEcCtD
Arformoterol—Skin disorder—Epirubicin—bone cancer	0.00126	0.00138	CcSEcCtD
Arformoterol—Insomnia—Methotrexate—bone cancer	0.00125	0.00137	CcSEcCtD
Arformoterol—Myalgia—Doxorubicin—bone cancer	0.00125	0.00137	CcSEcCtD
Arformoterol—Arthralgia—Doxorubicin—bone cancer	0.00125	0.00137	CcSEcCtD
Arformoterol—Chest pain—Doxorubicin—bone cancer	0.00125	0.00137	CcSEcCtD
Arformoterol—Anxiety—Doxorubicin—bone cancer	0.00125	0.00137	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00124	0.00136	CcSEcCtD
Arformoterol—Discomfort—Doxorubicin—bone cancer	0.00124	0.00136	CcSEcCtD
Arformoterol—Dyspnoea—Methotrexate—bone cancer	0.00123	0.00135	CcSEcCtD
Arformoterol—Somnolence—Methotrexate—bone cancer	0.00123	0.00135	CcSEcCtD
Arformoterol—Dry mouth—Doxorubicin—bone cancer	0.00122	0.00134	CcSEcCtD
Arformoterol—Dyspepsia—Methotrexate—bone cancer	0.00122	0.00134	CcSEcCtD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.00122	0.0137	CbGpPWpGaD
Arformoterol—Hypotension—Epirubicin—bone cancer	0.00121	0.00133	CcSEcCtD
Arformoterol—Anaphylactic shock—Doxorubicin—bone cancer	0.0012	0.00132	CcSEcCtD
Arformoterol—Oedema—Doxorubicin—bone cancer	0.0012	0.00132	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Methotrexate—bone cancer	0.0012	0.00131	CcSEcCtD
Arformoterol—Fatigue—Methotrexate—bone cancer	0.00119	0.00131	CcSEcCtD
Arformoterol—Infection—Doxorubicin—bone cancer	0.00119	0.00131	CcSEcCtD
Arformoterol—Pain—Methotrexate—bone cancer	0.00118	0.0013	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00118	0.0013	CcSEcCtD
Arformoterol—Nervous system disorder—Doxorubicin—bone cancer	0.00118	0.00129	CcSEcCtD
Arformoterol—Insomnia—Epirubicin—bone cancer	0.00117	0.00129	CcSEcCtD
Arformoterol—Tachycardia—Doxorubicin—bone cancer	0.00117	0.00128	CcSEcCtD
Arformoterol—Skin disorder—Doxorubicin—bone cancer	0.00116	0.00128	CcSEcCtD
Arformoterol—ADRB1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00116	0.013	CbGpPWpGaD
Arformoterol—Dyspnoea—Epirubicin—bone cancer	0.00116	0.00127	CcSEcCtD
Arformoterol—Somnolence—Epirubicin—bone cancer	0.00115	0.00126	CcSEcCtD
Arformoterol—Feeling abnormal—Methotrexate—bone cancer	0.00114	0.00125	CcSEcCtD
Arformoterol—Dyspepsia—Epirubicin—bone cancer	0.00114	0.00125	CcSEcCtD
Arformoterol—Gastrointestinal pain—Methotrexate—bone cancer	0.00113	0.00124	CcSEcCtD
Arformoterol—ADRB2—Arf6 signaling events—MET—bone cancer	0.00113	0.0128	CbGpPWpGaD
Arformoterol—ADRB2—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00113	0.0128	CbGpPWpGaD
Arformoterol—Hypotension—Doxorubicin—bone cancer	0.00112	0.00123	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Epirubicin—bone cancer	0.00112	0.00123	CcSEcCtD
Arformoterol—Fatigue—Epirubicin—bone cancer	0.00112	0.00123	CcSEcCtD
Arformoterol—Constipation—Epirubicin—bone cancer	0.00111	0.00122	CcSEcCtD
Arformoterol—Pain—Epirubicin—bone cancer	0.00111	0.00122	CcSEcCtD
Arformoterol—Urticaria—Methotrexate—bone cancer	0.0011	0.00121	CcSEcCtD
Arformoterol—Abdominal pain—Methotrexate—bone cancer	0.00109	0.0012	CcSEcCtD
Arformoterol—Body temperature increased—Methotrexate—bone cancer	0.00109	0.0012	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00109	0.0012	CcSEcCtD
Arformoterol—Insomnia—Doxorubicin—bone cancer	0.00108	0.00119	CcSEcCtD
Arformoterol—Dyspnoea—Doxorubicin—bone cancer	0.00107	0.00117	CcSEcCtD
Arformoterol—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00107	0.012	CbGpPWpGaD
Arformoterol—Feeling abnormal—Epirubicin—bone cancer	0.00107	0.00117	CcSEcCtD
Arformoterol—Somnolence—Doxorubicin—bone cancer	0.00107	0.00117	CcSEcCtD
Arformoterol—Gastrointestinal pain—Epirubicin—bone cancer	0.00106	0.00116	CcSEcCtD
Arformoterol—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00106	0.0119	CbGpPWpGaD
Arformoterol—Dyspepsia—Doxorubicin—bone cancer	0.00106	0.00116	CcSEcCtD
Arformoterol—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00105	0.0118	CbGpPWpGaD
Arformoterol—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00103	0.00114	CcSEcCtD
Arformoterol—Fatigue—Doxorubicin—bone cancer	0.00103	0.00113	CcSEcCtD
Arformoterol—Urticaria—Epirubicin—bone cancer	0.00103	0.00113	CcSEcCtD
Arformoterol—Constipation—Doxorubicin—bone cancer	0.00103	0.00112	CcSEcCtD
Arformoterol—Pain—Doxorubicin—bone cancer	0.00103	0.00112	CcSEcCtD
Arformoterol—ADRB2—GPCRs, Other—SMO—bone cancer	0.00103	0.0116	CbGpPWpGaD
Arformoterol—Abdominal pain—Epirubicin—bone cancer	0.00102	0.00112	CcSEcCtD
Arformoterol—Body temperature increased—Epirubicin—bone cancer	0.00102	0.00112	CcSEcCtD
Arformoterol—Hypersensitivity—Methotrexate—bone cancer	0.00102	0.00112	CcSEcCtD
Arformoterol—Asthenia—Methotrexate—bone cancer	0.000993	0.00109	CcSEcCtD
Arformoterol—Feeling abnormal—Doxorubicin—bone cancer	0.000988	0.00108	CcSEcCtD
Arformoterol—Gastrointestinal pain—Doxorubicin—bone cancer	0.00098	0.00108	CcSEcCtD
Arformoterol—Pruritus—Methotrexate—bone cancer	0.000979	0.00107	CcSEcCtD
Arformoterol—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000974	0.011	CbGpPWpGaD
Arformoterol—Hypersensitivity—Epirubicin—bone cancer	0.000954	0.00105	CcSEcCtD
Arformoterol—Urticaria—Doxorubicin—bone cancer	0.000952	0.00104	CcSEcCtD
Arformoterol—Body temperature increased—Doxorubicin—bone cancer	0.000948	0.00104	CcSEcCtD
Arformoterol—Abdominal pain—Doxorubicin—bone cancer	0.000948	0.00104	CcSEcCtD
Arformoterol—Diarrhoea—Methotrexate—bone cancer	0.000947	0.00104	CcSEcCtD
Arformoterol—Asthenia—Epirubicin—bone cancer	0.00093	0.00102	CcSEcCtD
Arformoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000928	0.0105	CbGpPWpGaD
Arformoterol—Pruritus—Epirubicin—bone cancer	0.000917	0.00101	CcSEcCtD
Arformoterol—Dizziness—Methotrexate—bone cancer	0.000915	0.001	CcSEcCtD
Arformoterol—Diarrhoea—Epirubicin—bone cancer	0.000886	0.000973	CcSEcCtD
Arformoterol—Hypersensitivity—Doxorubicin—bone cancer	0.000883	0.000969	CcSEcCtD
Arformoterol—Vomiting—Methotrexate—bone cancer	0.00088	0.000966	CcSEcCtD
Arformoterol—Rash—Methotrexate—bone cancer	0.000873	0.000958	CcSEcCtD
Arformoterol—Dermatitis—Methotrexate—bone cancer	0.000872	0.000957	CcSEcCtD
Arformoterol—Headache—Methotrexate—bone cancer	0.000867	0.000952	CcSEcCtD
Arformoterol—Asthenia—Doxorubicin—bone cancer	0.00086	0.000944	CcSEcCtD
Arformoterol—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000859	0.00968	CbGpPWpGaD
Arformoterol—Dizziness—Epirubicin—bone cancer	0.000857	0.00094	CcSEcCtD
Arformoterol—Pruritus—Doxorubicin—bone cancer	0.000848	0.000931	CcSEcCtD
Arformoterol—Vomiting—Epirubicin—bone cancer	0.000824	0.000904	CcSEcCtD
Arformoterol—Nausea—Methotrexate—bone cancer	0.000822	0.000902	CcSEcCtD
Arformoterol—Diarrhoea—Doxorubicin—bone cancer	0.00082	0.0009	CcSEcCtD
Arformoterol—Rash—Epirubicin—bone cancer	0.000817	0.000896	CcSEcCtD
Arformoterol—Dermatitis—Epirubicin—bone cancer	0.000816	0.000896	CcSEcCtD
Arformoterol—Headache—Epirubicin—bone cancer	0.000812	0.000891	CcSEcCtD
Arformoterol—Dizziness—Doxorubicin—bone cancer	0.000793	0.00087	CcSEcCtD
Arformoterol—Nausea—Epirubicin—bone cancer	0.00077	0.000844	CcSEcCtD
Arformoterol—Vomiting—Doxorubicin—bone cancer	0.000762	0.000836	CcSEcCtD
Arformoterol—Rash—Doxorubicin—bone cancer	0.000756	0.000829	CcSEcCtD
Arformoterol—Dermatitis—Doxorubicin—bone cancer	0.000755	0.000829	CcSEcCtD
Arformoterol—Headache—Doxorubicin—bone cancer	0.000751	0.000824	CcSEcCtD
Arformoterol—Nausea—Doxorubicin—bone cancer	0.000712	0.000781	CcSEcCtD
Arformoterol—ADRB1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000646	0.00729	CbGpPWpGaD
Arformoterol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000646	0.00728	CbGpPWpGaD
Arformoterol—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000637	0.00719	CbGpPWpGaD
Arformoterol—ADRB2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000632	0.00713	CbGpPWpGaD
Arformoterol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000594	0.0067	CbGpPWpGaD
Arformoterol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000589	0.00664	CbGpPWpGaD
Arformoterol—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000586	0.00661	CbGpPWpGaD
Arformoterol—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000581	0.00655	CbGpPWpGaD
Arformoterol—ADRB2—Arf6 signaling events—EGFR—bone cancer	0.000573	0.00647	CbGpPWpGaD
Arformoterol—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000524	0.0059	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—GRM4—bone cancer	0.000486	0.00548	CbGpPWpGaD
Arformoterol—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000482	0.00543	CbGpPWpGaD
Arformoterol—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000477	0.00538	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—GRM4—bone cancer	0.000476	0.00536	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.000456	0.00514	CbGpPWpGaD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.000451	0.00508	CbGpPWpGaD
Arformoterol—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.000445	0.00502	CbGpPWpGaD
Arformoterol—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.000445	0.00502	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—GRM1—bone cancer	0.000422	0.00475	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—GRM1—bone cancer	0.000412	0.00465	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.00039	0.0044	CbGpPWpGaD
Arformoterol—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000331	0.00373	CbGpPWpGaD
Arformoterol—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000302	0.0034	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—SMO—bone cancer	0.000297	0.00335	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—SMO—bone cancer	0.000291	0.00328	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000278	0.00314	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—GRM4—bone cancer	0.000275	0.0031	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—RGS1—bone cancer	0.000275	0.0031	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000274	0.00309	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NDUFA12—bone cancer	0.000273	0.00308	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—RGS1—bone cancer	0.000269	0.00303	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—GRM4—bone cancer	0.000269	0.00303	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000256	0.00288	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000254	0.00286	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000252	0.00284	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.00025	0.00282	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—GRM4—bone cancer	0.00025	0.00281	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—RGS1—bone cancer	0.00025	0.00281	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—RGS1—bone cancer	0.000244	0.00275	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—GRM4—bone cancer	0.000244	0.00275	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—GRM1—bone cancer	0.000238	0.00269	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000238	0.00268	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000235	0.00265	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—GRM1—bone cancer	0.000233	0.00263	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NT5C3A—bone cancer	0.000227	0.00255	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000219	0.00247	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000217	0.00245	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—GRM1—bone cancer	0.000216	0.00244	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000216	0.00243	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000214	0.00241	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—GRM1—bone cancer	0.000212	0.00239	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NDUFA12—bone cancer	0.000167	0.00188	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—GNA11—bone cancer	0.000154	0.00173	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000153	0.00173	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—SMO—bone cancer	0.000152	0.00172	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000152	0.00171	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—GNA11—bone cancer	0.00015	0.00169	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—SMO—bone cancer	0.000149	0.00168	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RGS1—bone cancer	0.000147	0.00166	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GRM4—bone cancer	0.000147	0.00166	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GRM4—bone cancer	0.000144	0.00163	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RGS1—bone cancer	0.000144	0.00163	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—GNA11—bone cancer	0.000139	0.00157	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—IL3—bone cancer	0.000139	0.00157	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NT5C3A—bone cancer	0.000138	0.00156	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—GNA11—bone cancer	0.000136	0.00154	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—IL3—bone cancer	0.000136	0.00154	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GRM1—bone cancer	0.000128	0.00144	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NT5C3A—bone cancer	0.000127	0.00143	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL3—bone cancer	0.000126	0.00143	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NT5C3A—bone cancer	0.000126	0.00142	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GRM1—bone cancer	0.000125	0.00141	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL3—bone cancer	0.000124	0.00139	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ENO2—bone cancer	9.92e-05	0.00112	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—DHFR—bone cancer	9.21e-05	0.00104	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SMO—bone cancer	9e-05	0.00102	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SMO—bone cancer	8.81e-05	0.000993	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GNA11—bone cancer	8.6e-05	0.00097	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GNA11—bone cancer	8.24e-05	0.000929	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GNA11—bone cancer	8.06e-05	0.000908	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP3A4—bone cancer	7.8e-05	0.00088	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ATF1—bone cancer	7.66e-05	0.000863	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ATF1—bone cancer	7.49e-05	0.000845	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL3—bone cancer	7.47e-05	0.000842	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL3—bone cancer	7.3e-05	0.000824	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTP1—bone cancer	6.67e-05	0.000752	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TGFBR2—bone cancer	6.39e-05	0.00072	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TGFBR2—bone cancer	6.25e-05	0.000704	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ENO2—bone cancer	6.05e-05	0.000682	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF1R—bone cancer	6.01e-05	0.000678	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF1R—bone cancer	5.88e-05	0.000663	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—DHFR—bone cancer	5.61e-05	0.000633	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ENO2—bone cancer	5.56e-05	0.000628	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ENO2—bone cancer	5.52e-05	0.000622	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GNA11—bone cancer	5.25e-05	0.000592	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—DHFR—bone cancer	5.16e-05	0.000582	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—DHFR—bone cancer	5.12e-05	0.000577	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GNA11—bone cancer	4.82e-05	0.000544	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GNA11—bone cancer	4.78e-05	0.000539	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP3A4—bone cancer	4.76e-05	0.000536	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.73e-05	0.000534	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP3A4—bone cancer	4.37e-05	0.000493	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KIT—bone cancer	4.36e-05	0.000491	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP3A4—bone cancer	4.34e-05	0.000489	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.31e-05	0.000487	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KIT—bone cancer	4.26e-05	0.000481	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BRAF—bone cancer	4.1e-05	0.000462	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—bone cancer	4.07e-05	0.000459	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BRAF—bone cancer	4.01e-05	0.000452	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EGFR—bone cancer	3.97e-05	0.000448	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EGFR—bone cancer	3.88e-05	0.000438	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—bone cancer	3.74e-05	0.000422	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—bone cancer	3.71e-05	0.000418	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—bone cancer	3.46e-05	0.00039	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MDM2—bone cancer	3.43e-05	0.000387	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MDM2—bone cancer	3.36e-05	0.000379	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUN—bone cancer	2.98e-05	0.000336	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUN—bone cancer	2.92e-05	0.000329	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—bone cancer	2.9e-05	0.000327	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—bone cancer	2.84e-05	0.00032	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGFR—bone cancer	2.35e-05	0.000264	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGFR—bone cancer	2.29e-05	0.000259	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—bone cancer	2.11e-05	0.000238	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—bone cancer	1.97e-05	0.000222	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—bone cancer	1.94e-05	0.000219	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—bone cancer	1.93e-05	0.000217	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—bone cancer	1.92e-05	0.000217	CbGpPWpGaD
